Loading insider details...
Beta
Latest Form 4 (Sep 1, 2026): Disposition to Issuer of 22,836 CRNX shares, $1.94M.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to Issuer | 22,836 | $1.94M |
| Jun 22, 2026 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/Award | 5,925 | n/a |
| Jun 11, 2026 | Atara Biotherapeutics, Inc. (ATRA) | Grant/Award | 12,000 | n/a |
| May 29, 2026 | Neumora Therapeutics, Inc. (NMRA) | Grant/Award | 80,000 | n/a |
| May 18, 2026 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/Award | 7,751 | n/a |
| Sep 30, 2025 | Crinetics Pharmaceuticals, Inc. (CRNX) | Exercise/Conversion | 10,000 | $19.1K |
| Jun 13, 2025 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/Award | 6,900 | n/a |
| Jun 13, 2025 | Atara Biotherapeutics, Inc. (ATRA) | Grant/Award | 7,828 | n/a |
| May 30, 2025 | Neumora Therapeutics, Inc. (NMRA) | Disposition to Issuer | 85,586 | n/a |
| May 19, 2025 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/Award | 5,740 | n/a |